Eidos Therapeutics, Inc. (EIDX) Financial Statements (2024 and earlier)

Company Profile

Business Address 101 MONTGOMERY STREET, SUITE 2550
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments174,821196,515191,157165,822131,400147,064
Cash and cash equivalents174,821196,515191,157165,822131,400147,064
Receivables154125858319772
Other undisclosed current assets3,8183,9524,6785,4023,9282,160
Total current assets:178,793200,592195,920171,307135,525149,296
Noncurrent Assets
Operating lease, right-of-use asset3,7813,8974,0104,121  
Property, plant and equipment1,3171,2831,2591,199204196
Other noncurrent assets2,7792,8252,6312,2672,5642,652
Other undisclosed noncurrent assets     9881,053
Total noncurrent assets:7,8778,0057,9007,5873,7563,901
TOTAL ASSETS:186,670208,597203,820178,894139,281153,197
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,8155,2865,4495,8803,1204,210
Employee-related liabilities1,2107301,8651,4161,102670
Accounts payable2,2403,9723,1513,5671,8423,212
Accrued liabilities5,365584433897176328
Debt  569554471  
Deferred compensation liability133138143145147147
Due to related parties359323316372344407
Other undisclosed current liabilities6,0825,5043,9683,2072,8783,077
Total current liabilities:15,38911,82010,43010,0756,4897,841
Noncurrent Liabilities
Long-term debt and lease obligation20,81520,75920,7034,736  
Long-term debt, excluding current maturities16,52216,31616,112   
Liabilities, other than long-term debt1,1551,1661,260129164201
Other liabilities316395129164201
Operating lease, liability4,2934,4434,5914,736  
Derivative instruments and hedges, liabilities1,1241,1031,165   
Other undisclosed noncurrent liabilities     782854
Total noncurrent liabilities:21,97021,92521,9634,8659461,055
Total liabilities:37,35933,74532,39314,9407,4358,896
Equity
Equity, attributable to parent149,311174,852171,427163,954131,846144,301
Common stock393938383737
Additional paid in capital304,050300,742274,494248,041222,865221,267
Accumulated deficit(154,778)(125,929)(103,105)(84,125)(91,056)(77,003)
Total equity:149,311174,852171,427163,954131,846144,301
TOTAL LIABILITIES AND EQUITY:186,670208,597203,820178,894139,281153,197

Income Statement (P&L) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues   26,691  
Cost of revenue
(Cost of Goods and Services Sold)
    (2,500)  
Gross profit:   24,191  
Operating expenses(28,397)(22,913)(19,344)(17,940)(14,794)(12,584)
Other undisclosed operating income 1562720   
Operating income (loss):(28,241)(22,886)(19,324)6,251(14,794)(12,584)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(4)580671680741851
Interest and debt expense(604)(518)    
Other undisclosed loss from continuing operations before equity method investments, income taxes   (327)   
Income (loss) from continuing operations:(28,849)(22,824)(18,980)6,931(14,053)(11,733)
Income (loss) before gain (loss) on sale of properties:(28,849)(22,824)(18,980)6,931(14,053)(11,733)
Net income (loss) available to common stockholders, diluted:(28,849)(22,824)(18,980)6,931(14,053)(11,733)

Comprehensive Income ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net income (loss):(28,849)(22,824)(18,980)6,931(14,053)(11,733)
Comprehensive income (loss), net of tax, attributable to parent:(28,849)(22,824)(18,980)6,931(14,053)(11,733)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: